. 2016 Feb 11;12:27–34. doi: 10.1007/s11888-016-0306-9

Table 1.

Studies examining PIK3CA mutation, aspirin use and colorectal cancer outcomes

Study	PIK3CA mutation (%)	PIK3CA mutant					PIK3CA wild type
Study	PIK3CA mutation (%)	No aspirin	Aspirin	Outcome	HR	95 % CI p value	No aspirin	Aspirin	Outcome	HR	95 % CI p value
NHS and HPFS [36]	16.7	95	66	OS	0.54	0.31–0.94 p = 0.01	466	337	OS	0.94	0.75–1.17 p = 0.96
NHS and HPFS [36]	16.7	95	66	CSS	0.18	0.06–0.61 p < 0.001	466	337	CSS	0.96	0.69–1.32 p = 0.76
VICTOR trial [37•]	11.6	90	14	OS	0.29	0.04–2.33 p = 0.19	681	111	OS	0.95	0.56–1.61 p = 0.26
VICTOR trial [37•]	11.6	90	14	CSS	0.11	0.001–0.83 p = 0.027	681	111	CSS	0.94	0.59–1.49 p = 0.79
MCS and RMH [38•]	12.4	136	49	OS	0.96	0.58–1.57 p = 0.86	Study of PIK3CA-mutated tumours only
MCS and RMH [38•]	12.4	136	49	CSS	0.60	0.34–1.16 p = 0.14	Study of PIK3CA-mutated tumours only
ECR^a [33••]	15.8	73	27	OS	0.73^b	0.33–1.63 p = 0.4	348	147	OS	0.55	0.40–0.75 p < 0.001

Multivariate (adjusted) statistics are presented in all cases

OS overall survival, CSS colorectal cancer-specific survival, RFS recurrence-free survival, NHS Nurses’ Health Study, HPFS Health Professionals Follow-up Study, MCS Moffitt Cancer Centre, RMH Royal Melbourne Hospital, ECR Eindhoven Cancer Registry, HR hazard ratio

^aColon cancer only

^bRate ratio